| Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia (NCT07735104) | Qilu Pharmaceutical Co., Ltd. | 2026-09-01 |
| A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases (NCT07751315) | Qilu Pharmaceutical Co., Ltd. | 2026-08-11 |
| Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) (NCT07730632) | Qilu Pharmaceutical Co., Ltd. | 2026-08-10 |
| QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ (NCT07716449) | Qilu Pharmaceutical Co., Ltd. | 2026-08-01 |
| QLF4113 in Participants With Metastatic Prostate Cancer (NCT07636707) | Qilu Pharmaceutical Co., Ltd. | 2026-07-20 |
| Phase II Study of QLC2519 in Pediatric Solid Tumor Participants (NCT07724756) | Qilu Pharmaceutical Co., Ltd. | 2026-06-26 |
| QLC5508 in Participants With Metastatic Prostate Cancer (NCT07632690) | Qilu Pharmaceutical Co., Ltd. | 2026-06-20 |
| A Phase 3 Clinical Study of QL2106 Injection (NCT07511647) | Qilu Pharmaceutical Co., Ltd. | 2026-06-15 |
| QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (NCT07620041) | Qilu Pharmaceutical Co., Ltd. | 2026-06-05 |
| To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3) (NCT07620366) | Qilu Pharmaceutical Co., Ltd. | 2026-06-01 |
| QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms (NCT07560449) | Qilu Pharmaceutical Co., Ltd. | 2026-06-01 |
| Study of QLS1410 in the Treatment of Primary Aldosteronism. (NCT07550465) | Qilu Pharmaceutical Co., Ltd. | 2026-06-01 |
| QLS5212 for Participants With Advanced Solid Tumors (NCT07467629) | Qilu Pharmaceutical Co., Ltd. | 2026-05-11 |
| QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) (NCT07450378) | Qilu Pharmaceutical Co., Ltd. | 2026-05-01 |
| A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations (NCT07585565) | Qilu Pharmaceutical Co., Ltd. | 2026-05-01 |
| QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (NCT07463573) | Qilu Pharmaceutical Co., Ltd. | 2026-04-20 |
| Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (NCT07455006) | Qilu Pharmaceutical Co., Ltd. | 2026-04-20 |
| A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis (NCT07344051) | Qilu Pharmaceutical Co., Ltd. | 2026-04-05 |
| QLS1410 in Participants With Uncontrolled Hypertension (NCT07489612) | Qilu Pharmaceutical Co., Ltd. | 2026-04-01 |
| QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa (NCT07417917) | Qilu Pharmaceutical Co., Ltd. | 2026-04-01 |
| QLS5132 Combination Therapy in Advanced Solid Tumors (NCT07453394) | Qilu Pharmaceutical Co., Ltd. | 2026-04-01 |
| Study of QLS5308 in Patients With Advanced Solid Tumors (NCT07462442) | Qilu Pharmaceutical Co., Ltd. | 2026-03-28 |
| QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia (NCT07444086) | Qilu Pharmaceutical Co., Ltd. | 2026-03-05 |
| QLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis (NCT07377773) | Qilu Pharmaceutical Co., Ltd. | 2026-03-05 |
| A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease (NCT07489599) | Qilu Pharmaceutical Co., Ltd. | 2026-03-01 |
| QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C) (NCT07441317) | Qilu Pharmaceutical Co., Ltd. | 2026-03-01 |
| A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (NCT07489586) | Qilu Pharmaceutical Co., Ltd. | 2026-03-01 |
| Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients (NCT07235176) | Qilu Pharmaceutical Co., Ltd. | 2026-01-16 |
| A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies (NCT07294300) | Qilu Pharmaceutical Co., Ltd. | 2026-01-01 |
| Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults (NCT07331545) | Qilu Pharmaceutical Co., Ltd. | 2026-01-01 |
| First in Human Study of QLS5316 in Solid Tumors (NCT07358884) | Qilu Pharmaceutical Co., Ltd. | 2026-01-01 |
| A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults (NCT07313150) | Qilu Pharmaceutical Co., Ltd. | 2026-01-01 |
| A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia (NCT07345000) | Qilu Pharmaceutical Co., Ltd. | 2026-01-01 |
| A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) (NCT07300111) | Qilu Pharmaceutical Co., Ltd. | 2025-12-31 |
| Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors (NCT07272590) | Qilu Pharmaceutical Co., Ltd. | 2025-12-30 |
| Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma (NCT07302516) | Qilu Pharmaceutical Co., Ltd. | 2025-12-25 |
| A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies (NCT07173595) | Qilu Pharmaceutical Co., Ltd. | 2025-12-05 |
| A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects (NCT07479576) | Qilu Pharmaceutical Co., Ltd. | 2025-11-10 |
| A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma (NCT07138209) | Qilu Pharmaceutical Co., Ltd. | 2025-11-07 |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (NCT07198633) | Qilu Pharmaceutical Co., Ltd. | 2025-11-05 |
| A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (NCT07256782) | Qilu Pharmaceutical Co., Ltd. | 2025-10-24 |
| Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer (NCT07104110) | Qilu Pharmaceutical Co., Ltd. | 2025-10-01 |
| Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants (NCT07124468) | Qilu Pharmaceutical Co., Ltd. | 2025-09-13 |
| Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma (NCT07018050) | Qilu Pharmaceutical Co., Ltd. | 2025-09-12 |
| A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer (NCT07079228) | Qilu Pharmaceutical Co., Ltd. | 2025-09-08 |
| Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer (NCT07151872) | Qilu Pharmaceutical Co., Ltd. | 2025-09-01 |
| Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) (NCT07162883) | Qilu Pharmaceutical Co., Ltd. | 2025-09-01 |
| A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer (NCT07173556) | Qilu Pharmaceutical Co., Ltd. | 2025-09-01 |
| Pharmacokinetics and Pharmacodynamics Study (NCT07074236) | Qilu Pharmaceutical Co., Ltd. | 2025-07-01 |
| A Study of QLS5133 Monotherapy in Advanced Solid Tumors (NCT07061639) | Qilu Pharmaceutical Co., Ltd. | 2025-07-01 |
| A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® (NCT07062978) | Qilu Pharmaceutical Co., Ltd. | 2025-06-27 |
| To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy (NCT06940336) | Qilu Pharmaceutical Co., Ltd. | 2025-06-19 |
| A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (NCT06954246) | Qilu Pharmaceutical Co., Ltd. | 2025-06-04 |
| A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus (NCT07001839) | Qilu Pharmaceutical Co., Ltd. | 2025-06-01 |
| To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture (NCT06898060) | Qilu Pharmaceutical Co., Ltd. | 2025-06-01 |
| The Food Effect on Pharmacokinetics Study of QLC1101 in Healthy Subjects (NCT06980909) | Qilu Pharmaceutical Co., Ltd. | 2025-06-01 |
| Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT06942767) | Qilu Pharmaceutical Co., Ltd. | 2025-06-01 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation (NCT06949761) | Qilu Pharmaceutical Co., Ltd. | 2025-06-01 |
| Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis (NCT06880276) | Qilu Pharmaceutical Co., Ltd. | 2025-05-16 |
| A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients (NCT06911827) | Qilu Pharmaceutical Co., Ltd. | 2025-05-09 |
| Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors (NCT06932094) | Qilu Pharmaceutical Co., Ltd. | 2025-05-01 |
| Study on the Efficacy and Safety of QLM1016 in Schizophrenia (NCT06799559) | Qilu Pharmaceutical Co., Ltd. | 2025-05-01 |
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections (NCT07089186) | Qilu Pharmaceutical Co., Ltd. | 2025-04-12 |
| Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers (NCT06864793) | Qilu Pharmaceutical Co., Ltd. | 2025-04-06 |
| A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors (NCT06872580) | Qilu Pharmaceutical Co., Ltd. | 2025-04-01 |
| Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors (NCT06823609) | Qilu Pharmaceutical Co., Ltd. | 2025-03-06 |
| QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma (NCT06852456) | Qilu Pharmaceutical Co., Ltd. | 2025-03-01 |
| Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol (NCT06750341) | Qilu Pharmaceutical Co., Ltd. | 2025-02-01 |
| Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer (NCT06837896) | Qilu Pharmaceutical Co., Ltd. | 2025-02-01 |
| a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. (NCT06789796) | Qilu Pharmaceutical Co., Ltd. | 2025-02-01 |
| A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC (NCT06754644) | Qilu Pharmaceutical Co., Ltd. | 2025-01-15 |
| To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (NCT07081256) | Qilu Pharmaceutical Co., Ltd. | 2025-01-03 |
| To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma (NCT06742138) | Qilu Pharmaceutical Co., Ltd. | 2025-01-01 |
| A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer (NCT06686576) | Qilu Pharmaceutical Co., Ltd. | 2024-12-12 |
| Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib (NCT06644495) | Qilu Pharmaceutical Co., Ltd. | 2024-12-01 |
| A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia (NCT06649214) | Qilu Pharmaceutical Co., Ltd. | 2024-11-01 |
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI (NCT06633718) | Qilu Pharmaceutical Co., Ltd. | 2024-10-31 |
| QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (NCT06456528) | Qilu Pharmaceutical Co., Ltd. | 2024-10-22 |
| A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent® (NCT06614907) | Qilu Pharmaceutical Co., Ltd. | 2024-08-31 |
| A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma (NCT06500507) | Qilu Pharmaceutical Co., Ltd. | 2024-08-30 |
| A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer (NCT06383767) | Qilu Pharmaceutical Co., Ltd. | 2024-07-11 |
| Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors (NCT06446388) | Qilu Pharmaceutical Co., Ltd. | 2024-06-30 |
| A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers (NCT06232902) | Qilu Pharmaceutical Co., Ltd. | 2024-06-20 |
| A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors (NCT06394713) | Qilu Pharmaceutical Co., Ltd. | 2024-06-15 |
| A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors (NCT06403735) | Qilu Pharmaceutical Co., Ltd. | 2024-04-25 |
| A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults (NCT06371534) | Qilu Pharmaceutical Co., Ltd. | 2024-04-12 |
| A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma (NCT06261359) | Qilu Pharmaceutical Co., Ltd. | 2024-03-19 |
| Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (NCT06671548) | Qilu Pharmaceutical Co., Ltd. | 2024-01-15 |
| A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis (NCT06406205) | Qilu Pharmaceutical Co., Ltd. | 2023-12-25 |
| A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis (NCT06058000) | Qilu Pharmaceutical Co., Ltd. | 2023-11-13 |
| A Study of QL1706H in Patients With Advanced Solid Tumors (NCT06047431) | Qilu Pharmaceutical Co., Ltd. | 2023-10-01 |
| A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors (NCT06041035) | Qilu Pharmaceutical Co., Ltd. | 2023-10-01 |
| Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer (NCT05973149) | Qilu Pharmaceutical Co., Ltd. | 2023-08-31 |
| A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children (NCT06151587) | Qilu Pharmaceutical Co., Ltd. | 2023-08-20 |
| A Study of QLF3108 in Participants With Advanced Solid Tumor (NCT06019013) | Qilu Pharmaceutical Co., Ltd. | 2023-08-16 |
| Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes (NCT05950516) | Qilu Pharmaceutical Co., Ltd. | 2023-07-10 |
| Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors (NCT05884801) | Qilu Pharmaceutical Co., Ltd. | 2023-06-30 |
| A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma (NCT05920876) | Qilu Pharmaceutical Co., Ltd. | 2023-06-30 |
| Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects (NCT05932888) | Qilu Pharmaceutical Co., Ltd. | 2023-06-25 |
| Study of MHB088C for Patients With Advanced Solid Malignant Tumors (NCT07102004) | Qilu Pharmaceutical Co., Ltd. | 2023-06-20 |